Cart
sales@molnova.com
Nebularine
CAS No. 550-33-4
Nebularine( —— )
Catalog No. M37875 CAS No. 550-33-4
Nebularine (9-(beta-D-Ribofuranosyl)-9H-purine) is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting inert lymphoid malignancies and inducing apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 38 | In Stock |
|
| 25MG | 77 | In Stock |
|
| 50MG | 120 | In Stock |
|
| 100MG | 198 | In Stock |
|
| 200MG | 296 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNebularine
-
NoteResearch use only, not for human use.
-
Brief DescriptionNebularine (9-(beta-D-Ribofuranosyl)-9H-purine) is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting inert lymphoid malignancies and inducing apoptosis.
-
DescriptionNebularine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | DNA/RNA Synthesis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number550-33-4
-
Formula Weight252.23
-
Molecular FormulaC10H12N4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2cncnc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.?
molnova catalog
related products
-
AOH1996
AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC).
-
Eriocalyxin B
Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, should be considered a candidate for pancreatic cancer treatment.
-
PI3Kδ-IN-16
PI3Kδ-IN-16 is a selective and potent PI3Kδ inhibitor with anticancer and antiproliferative activity, induces cell cycle arrest and apoptosis.
